Aker BioMarine will release its Q1/21 results on 29 April. We expect an adj. EBITDA of UD 11.5m – slightly above consensus at USD 10.5m. We still expect strong earnings growth in the years ahead supported by higher catch volumes and a shift towards higher margin products. Short-term, our main attention will be towards a sales recovery of Superba as well as the Brands segment. We stick to Buy as well as our NOK 185 target price in this preview.
